Company Overview
- Business Name
- BioBank Co., Ltd.
- Head Office
- 388-1 Hirata, Kita-ku, Okayama-shi, Okayama 700-0952, JAPAN
- TEL
- +81-86-239-4141
- FAX
- +81-86-805-6005
- URL
- https://www.omx.co.jp/en/
- Representative
- Masaki Morita, Chief Executive Officer
- Established
- June 22, 1974
- Capital
- 10,000,000 yen
- Main Business
-
- Manufacturing, sales, import and export of fermented amino acid foods and microbes required for crop production
- Research, study and consultancy on utilization of microbes
- Sales, import and export of health foods and drinks
- Manufacturing, sales, import and export of products containing lactic acid bacteria, yeast, microbes and dietary fibers
- Manufacturing, sales, import and export of cosmetics, pharmaceuticals, quasi-drugs, and cosmetic tools
- Shareholder
- NIITAKA Co., Ltd. (100%)
- Joint Research Partners
- Okayama University, University of Lille, Harvard University, Hokkaido University of Science, Azabu University, Kinki University, Mie University, and others.
- Joint Research Partners
- MUFG Bank, Ltd.
The Chugoku Bank, Ltd.
The Shikoku Bank, Ltd.
Business Continuity Policy
BioBank Co., Ltd. (hereinafter referred to as "BioBank") is engaged in the manufacture and sale of
plant-fermented extract supplements. BioBank recognizes that any disruption to these activities could
make a significant impact on its customers' business activities and may result in a loss of their trust.
To address such threats that could disrupt our activities, BioBank has set up a Business Continuity
Plan (BCP) based on the Business Continuity Policy, and is committed to continual improvement of its BCP
in response to changes in both internal and external environments.
1. Prevention and Correction of Disruptions
BioBank identifies critical activities that must be prioritized for continuity and recovery. BioBank conducts comprehensive risk assessments related to potential disruptions and implements appropriate and proportionate control measures. In preparation for emergencies, BioBank establishes and maintains clear response frameworks and documented procedures to prevent business disruptions and achieve recovery within the recovery time objective . Where new risks that may cause an impact on business continuity are identified, corrective actions shall be implemented in a timely manner.
＜Scope of the BCP (as of the latest revision date)＞
- a. Organization
- BioBank Co., Ltd.
- b. Locations:
-
- Head Office (388-1 Hirata, Kita-ku, Okayama-shi, Okayama, Japan)
- Hirata Factory (388-1 Hirata, Kita-ku, Okayama-shi, Okayama, Japan)
- Kuwano Factory (702-1 Kuwano, Naka-ku, Okayama-shi, Okayama, Japan)
- c. Activities
- Manufacture and sales of plant-fermented extract supplements
- d. Assets
- All employees and operational equipment related to the above business activities
2. Enhancing Awareness and Organizational Response Capabilities Regarding Business Continuity
BioBank conducts regular training and exercises related to the BCP to enhance employee awareness of business continuity and strengthen organizational response capability.
3. Compliance and Commitment to Sustainability
In establishing and maintaining the BCP, BioBank complies with applicable legal and regulatory requirements, as well as relevant domestic and international guidelines and other applicable obligations pertaining to business continuity. BioBank also strives to strengthen its resilience and adaptive capacity against climate-related and natural disasters, contributing to the achievement of the Sustainable Development Goals (SDGs).
4. Inquiries
For inquiries regarding BioBank's business continuity, please contact us at: https://www.omx.co.jp/contact/
5. Continual Improvement of the BCP
BioBank continuously reviews and improves the effectiveness of its BCP by taking account of changes in business activities, the social environment, and internal and external inquiries.
Masaki Morita
Chief Executive Officer
BioBank Co., Ltd.
Date of Enactment:
September 29, 2025
Last Revised: March 30, 2026
Credentials
To guarantee the provision of high-quality services to our customers, we have adopted a quality management system compliant with the international standard ISO 9001 and strive for continuous operational improvement. All our employees will continue to work diligently to deliver safe products to everyone.
BioBank Co., Ltd. has obtained and operates under the "ISO 9001:2015" certification for the development
and manufacturing of health foods and cosmetics. We have also obtained "Health Food GMP" certification,
which certifies that manufacturing is conducted appropriately.
BioBank Co., Ltd. is certified under
the "Health Food GMP" operated by the Japan Institute of Health Food Standards (JIHFS*).
*This certification confirms compliance with GMP standards following rigorous audits
based on the JIHFS Health Food GMP Code.
The JIHFS GMP Code conforms to the Ministry of Health,
Labour and Welfare's Health Food GMP Guidelines.
Manufacturing Facilities: Hirata Fermentation
Brewery, Kuwano Fermentation Brewery
（General Incorporated Association The Japanese Institute for Health Food Standards）
Online sales of health supplements and cosmetics
CSR
First Company in the Health Supplement Industry to Join UN WFP Activities
The United Nations World Food Programme (WFP) is the world's leading humanitarian organization
dedicated to achieving zero hunger. In times of disasters and conflicts, WFP delivers
life-saving food assistance, while its School Meals Programme helps improve children's nutrition
and expand access to education.
As the first partner from Japan's health supplement industry, BioBank supports WFP's School
Meals Programme through the Red Cup Campaign, contributing to a better future for children
around the world.